All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional.
Introducing
Now you can personalise
your GvHD Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe GvHD Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the GvHD Hub cannot guarantee the accuracy of translated content. The GvHD Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Bookmark this article
Did you miss ASH 2018? The GvHD Hub attended the 60th ASH Annual Meeting & Exposition, December 1–4 2018, San Diego, CA, USA, and has developed a downloadable resource, which provides information on the practice changing abstracts across graft-versus-host disease (GvHD).
Our selection of ASH abstracts include comments from The GvHD Hub Steering Committee members on promising new therapeutic and prophylactic options; ruxolitinib for steroid refractory GvHD, KD025 for chronic GvHD, and vedolizumab for GvHD prophylaxis. Hear from the experts on the role of the microbiome, genetic risk factors and potential biomarkers in GvHD.
ASH 2018 | Practice changing abstracts in graft-versus-host disease
If you would like to view the ASH 2018 highlights, practice changing abstracts and expert opinions please find the GvHD Hub resource below:
Download Herehttp://www.gvhdhub.com/medical-information/ash-2018-ruxolitinib-plus-corticosteroids-in-patients-with-steroid-refractory-acute-graft-versus-host-disease-the-reach1-trial
http://www.gvhdhub.com/medical-information/ash-2018-pharmacodynamics-and-updated-data-from-the-phase-iia-kd025-208-trial
http://www.gvhdhub.com/medical-information/ash-2018-vedolizumab-plus-standard-of-care-to-prevent-graft-versus-host-disease-a-phase-ib-study
http://www.gvhdhub.com/medical-information/ash-2018-msc-ffm-for-the-treatment-of-pediatric-and-adult-patients-with-steroid-refractory-graft-versus-host-disease
http://www.gvhdhub.com/medical-information/ash-2018-the-role-of-metabolomics-profiling-in-acute-graft-versus-host-disease
http://www.gvhdhub.com/medical-information/kate-a-markey-ash-2018-pre-transplant-and-peri-d100-gastrointestinal-dysbiosis-in-chronic-gvhd
https://gvhdhub.com/medical-information/prediction-of-severe-chronic-graft-versus-host-disease-by-host-derived-cxcr3-ligand-genes
https://gvhdhub.com/medical-information/james-ferrara-ash-2018-how-biology-drives-acute-gvhd-biomarkers
Subscribe to get the best content related to GvHD delivered to your inbox